Facebook Pixel Code
Banner image
Adeli Lab

Hypolipidemic drugs

Mechanisms of Action of Hypolipidemic Drugs at the cellular and molecular level

Comparison of efficacy of pharmaceuticals in lowering plasma levels of atherogenic lipoproteins and their potienal in raising anti-atherogenic lipoproteins.

We have employed the model systems developed in our laboratory over the past several years to investigate the mechanisms of action of a number of pharmaceutical drugs used as hypolipidemic agents in patients with high plasma cholesterol and/or triglyceride levels.

Up to the present time we have studied the mechanisms of action of a number of HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin, rosuvastatin), fibrates (fenofibrate), and insulin sensitizers (rosiglitazone). These studies have been supported by a number of grants and contracts from pharmaceutical companies including Parke-Davis, Pizer, Merck, and Smith-Kline Beecham.